All In MedTech

Device Trial Radar · NCT07460583

ProActive Athlete Heart Program: Proposal for Cardiac Risk Screening in Former High-Intensity Athletes

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 28, 2027

Primary completion

Jan 31, 2027

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Baylor Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cleerly, Inc.
First posted
Mar 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated device
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AI-Guided Coronary CT Angiography Screening in Former High-Intensity Athletes

Conditions

  • Coronary Atherosclerosis Due to Calcified Coronary Lesion

Interventions

  • Coronary CTADevice

    The Coronary CTA will be performed for each participant. These images will be analyzed using AI-software to assess plaque quantification and an ischemia analysis, if necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of Coronary AtherosclerosisTime frame: At CCTA assessment
  2. Coronary Atherosclerosis CharacteristicsTime frame: At CCTA Assessment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.